{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:10:50Z","timestamp":1784128250499,"version":"3.55.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:p>A previously healthy woman in her 30s presented with a diffuse maculopapular rash, most prominently on her legs, with pitted necrotic spots, black eschar, and serous fluid weeping with diffuse edema. Histopathology showed areas with abnormal aggregates composed almost entirely of small T cells with no significant cytomorphologic atypia and numerous admixed eosinophils. What is your diagnosis?<\/jats:p>","DOI":"10.1001\/jamadermatol.2026.0381","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:27Z","timestamp":1779895827000},"page":"743","source":"Crossref","is-referenced-by-count":0,"title":["Diffuse Pruritic Maculopapular Rash With Pitted Necrosis"],"prefix":"10.1001","volume":"162","author":[{"given":"Taylor","family":"Skinner","sequence":"first","affiliation":[{"name":"Discipline of Medicine, Memorial University of Newfoundland, St John\u2019s, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Liwski","sequence":"additional","affiliation":[{"name":"Division of Hematological Pathology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Y. C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Coastal Program for Rare Inflammatory Diseases, Nova Scotia Health Research & Innovation Hub, Halifax, Nova Scotia, Canada"},{"name":"Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"15","key":"dcg260006r1","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.","volume":"341","author":"Simon","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"dcg260006r2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/ejh.13437","article-title":"Causes of hypereosinophilia in 100 consecutive patients.","volume":"105","author":"Moller","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"dcg260006r3","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.1109","article-title":"Lymphocytic variant hypereosinophilic syndrome.","volume":"6","author":"Wang","year":"2025","journal-title":"EJHaem"},{"issue":"2","key":"dcg260006r4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/ajcp\/aqaa227","article-title":"Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome.","volume":"155","author":"King","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"dcg260006r5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jdv.16969","article-title":"Primary cutaneous peripheral T-cell lymphoma, not otherwise specified.","volume":"35","author":"Kempf","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"dcg260006r6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2249.2000.01260.x","article-title":"Accumulation of CD4+CD7- T cells in inflammatory skin lesions.","volume":"121","author":"Liu","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"dcg260006r7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjh.17615","article-title":"Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES).","volume":"195","author":"Williams","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"dcg260006r8","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1111\/bjh.16332","article-title":"Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome.","volume":"188","author":"Choi","year":"2020","journal-title":"Br J Haematol"},{"key":"dcg260006r9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109275","article-title":"JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome.","volume":"251","author":"Faguer","year":"2023","journal-title":"Clin Immunol"},{"issue":"4","key":"dcg260006r10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jaci.2024.12.1085","article-title":"Mepolizumab in patients with lymphoid-variant hypereosinophilic syndrome.","volume":"155","author":"Catherine","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2849569\/jamadermatology_skinner_2026_cg_260006_1783528921.82061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:42Z","timestamp":1784127642000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2849569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0381","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}